Tags

Type your tag names separated by a space and hit enter

Current treatments of chronic immune-mediated demyelinating polyneuropathies.
Muscle Nerve. 2009 May; 39(5):563-78.MN

Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN), and anti-myelin-associated glycoprotein (anti-MAG) neuropathy are three demyelinating acquired neuropathies, with distinct responses to immunotherapy. In placebo-controlled, double-blind, randomized trials, intravenous immunoglobulin (IVIg) has been effective for CIDP and MMN, and plasmapheresis has been effective for CIDP. Corticosteroids have been beneficial in controlled trials for CIDP. Other agents, including cyclophosphamide, rituximab, azathioprine, cyclosporine, interferons, fludarabine, mycophenolate mofetil, and etanercept, have been reported to benefit some patients with inflammatory demyelinating neuropathies in case series and case reports. This review examines the use and toxicity associated with these immunotherapy medications in treating patients with chronic immune-mediated demyelinating neuropathies. Muscle Nerve, 2009.

Authors+Show Affiliations

Peripheral Neuropathy Center, Neurological Institute, Columbia University College of Physicians and Surgeons, 710 West 168th Street, Box 163, New York, New York 10032, USA. tb2325@columbia.edu

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19301378

Citation

Brannagan, Thomas H.. "Current Treatments of Chronic Immune-mediated Demyelinating Polyneuropathies." Muscle & Nerve, vol. 39, no. 5, 2009, pp. 563-78.
Brannagan TH. Current treatments of chronic immune-mediated demyelinating polyneuropathies. Muscle Nerve. 2009;39(5):563-78.
Brannagan, T. H. (2009). Current treatments of chronic immune-mediated demyelinating polyneuropathies. Muscle & Nerve, 39(5), 563-78. https://doi.org/10.1002/mus.21277
Brannagan TH. Current Treatments of Chronic Immune-mediated Demyelinating Polyneuropathies. Muscle Nerve. 2009;39(5):563-78. PubMed PMID: 19301378.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current treatments of chronic immune-mediated demyelinating polyneuropathies. A1 - Brannagan,Thomas H,3rd PY - 2009/3/21/entrez PY - 2009/3/21/pubmed PY - 2009/6/10/medline SP - 563 EP - 78 JF - Muscle & nerve JO - Muscle Nerve VL - 39 IS - 5 N2 - Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN), and anti-myelin-associated glycoprotein (anti-MAG) neuropathy are three demyelinating acquired neuropathies, with distinct responses to immunotherapy. In placebo-controlled, double-blind, randomized trials, intravenous immunoglobulin (IVIg) has been effective for CIDP and MMN, and plasmapheresis has been effective for CIDP. Corticosteroids have been beneficial in controlled trials for CIDP. Other agents, including cyclophosphamide, rituximab, azathioprine, cyclosporine, interferons, fludarabine, mycophenolate mofetil, and etanercept, have been reported to benefit some patients with inflammatory demyelinating neuropathies in case series and case reports. This review examines the use and toxicity associated with these immunotherapy medications in treating patients with chronic immune-mediated demyelinating neuropathies. Muscle Nerve, 2009. SN - 0148-639X UR - https://www.unboundmedicine.com/medline/citation/19301378/Current_treatments_of_chronic_immune_mediated_demyelinating_polyneuropathies_ L2 - https://doi.org/10.1002/mus.21277 DB - PRIME DP - Unbound Medicine ER -